High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

The use of high-dose chemotherapy and transplantation for chemotherapy sensitive relapsed diffuse large-cell non-Hodgkin's lymphoma is now the gold standard for patients who are candidates for such therapy. Recent data also demonstrates the relative effectiveness of this approach for patients who are induction failures but are continuing to respond to conventional therapy at the time of transplantation. Newer approaches such as the use of novel agents to modify the transplant regimen, newer cytokines, or alternative sources of hematopoietic stem cells need to be tested in order to improve the outcome in patients with chemotherapy resistant disease.

Original languageEnglish (US)
Pages (from-to)S1-S3
JournalAnnals of Oncology
Volume9
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 1998

Fingerprint

Hematopoietic Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Drug Therapy
Transplantation
Hematopoietic Stem Cells
Cytokines
Transplants
Therapeutics

Keywords

  • Autologous transplant
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

@article{4726d3a98d00412bb362fab1da5c1f60,
title = "High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma",
abstract = "The use of high-dose chemotherapy and transplantation for chemotherapy sensitive relapsed diffuse large-cell non-Hodgkin's lymphoma is now the gold standard for patients who are candidates for such therapy. Recent data also demonstrates the relative effectiveness of this approach for patients who are induction failures but are continuing to respond to conventional therapy at the time of transplantation. Newer approaches such as the use of novel agents to modify the transplant regimen, newer cytokines, or alternative sources of hematopoietic stem cells need to be tested in order to improve the outcome in patients with chemotherapy resistant disease.",
keywords = "Autologous transplant, Non-Hodgkin's lymphoma",
author = "Vose, {Julie Marie}",
year = "1998",
month = "1",
day = "1",
doi = "10.1093/annonc/9.suppl_1.S1",
language = "English (US)",
volume = "9",
pages = "S1--S3",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma

AU - Vose, Julie Marie

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The use of high-dose chemotherapy and transplantation for chemotherapy sensitive relapsed diffuse large-cell non-Hodgkin's lymphoma is now the gold standard for patients who are candidates for such therapy. Recent data also demonstrates the relative effectiveness of this approach for patients who are induction failures but are continuing to respond to conventional therapy at the time of transplantation. Newer approaches such as the use of novel agents to modify the transplant regimen, newer cytokines, or alternative sources of hematopoietic stem cells need to be tested in order to improve the outcome in patients with chemotherapy resistant disease.

AB - The use of high-dose chemotherapy and transplantation for chemotherapy sensitive relapsed diffuse large-cell non-Hodgkin's lymphoma is now the gold standard for patients who are candidates for such therapy. Recent data also demonstrates the relative effectiveness of this approach for patients who are induction failures but are continuing to respond to conventional therapy at the time of transplantation. Newer approaches such as the use of novel agents to modify the transplant regimen, newer cytokines, or alternative sources of hematopoietic stem cells need to be tested in order to improve the outcome in patients with chemotherapy resistant disease.

KW - Autologous transplant

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0031953768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031953768&partnerID=8YFLogxK

U2 - 10.1093/annonc/9.suppl_1.S1

DO - 10.1093/annonc/9.suppl_1.S1

M3 - Review article

C2 - 9581234

AN - SCOPUS:0031953768

VL - 9

SP - S1-S3

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 1

ER -